Review
BibTex RIS Cite

3 Doz mRNA COVID-19 Aşısı ve SARS-CoV-2 Omicron Varyantı Enfeksiyonu Arasındaki İlişki

Year 2022, Volume: 31 Issue: 4, 249 - 253, 30.12.2022
https://doi.org/10.17827/aktd.1097876

Abstract

Aralık 2021'de SARS-CoV-2 Omicron varyantı, COVID-19 pandemisinde küresel olarak baskın hale gelerek Delta varyantını hızla geride bıraktı. Omicron varyantı, mutasyonları nedeniyle aşıların koruyuculuğunu azaltma konusunda ciddi endişeler uyandırmıştır. Yeni veriler, aşısızlara ve 2 doz aşılılara göre 3 doz mRNA aşısı olunmasının, Omicron varyantına karşı korunma ile ilişkili olduğunu göstermekte, 3 dozluk programların koruyucu olduğunu destekleyen kanıtlar sağlamaktadır. Bu nedenle Omicron'a karşı korumayı artırmada sürekli rolü olan COVID-19 aşılarının hızlandırılmış ve adil bir şekilde piyasaya sürülmesi önerilmektedir. Bu derlemede 3 doz mRNA COVID-19 aşısı ile SARS-CoV-2 Omicron varyantının neden olduğu enfeksiyon arasındaki ilişki incelenmiş ve çözüm önerileri getirilmiştir.

References

  • 1. Vitiello, A., Ferrara, F., Auti, A. M., Di Domenico, M., & Boccellino, M. Advances in the Omicron variant development. J Intern Med. 2022.
  • 2. Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G. et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327(7):639-651.
  • 3. Chenchula, S., & Karunakaran, P. Current Evidence on Efficacy of COVID‐19 Booster Dose Vaccination Against the Omicron Variant. A Systematic Review. J Med Virol. 2022.
  • 4. Shen, X. Boosting immunity to Omicron. Nat Med. 2022;1-2.
  • 5. Hart, J. D., Chokephaibulkit, K., Mayxay, M., Ong-Lim, A. L. T., Saketa, S. T., Russell F. M. COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron. Lancet Reg Health West Pac. 2022;100404.
  • 6. Mehta, S., Gambhir, R. S., Singh, B., Goel, R., Ghuman, K. S., Aggarwal, A. COVID-19 Update: Omicron Variant–A New Emerging Threat. Rocz Panstw Zakl Hig. 2022;73(1):13-16.
  • 7. Chavda, V. P., & Apostolopoulos, V. Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?. Vaccines. 2022;10(3):367.
  • 8. Our World In Data. Avaible from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL . Accessed: 23.03.2022.
  • 9. Vaccine Tracker ECDC. Avaible from: https://vaccinetracker.ecdc.europa.eu/public/extensions/covid-19/vaccine-tracker.html#uptake-tab . Accessed: 23.03.2022.
  • 10. COVID CDC. Avaible from: https://covid.cdc.gov/covid-data-tracker/ . Accessed: 23.03.2022.
  • 11. WHO South East Asia. Avaible from: https://www.who.int/southeastasia/health-topics/immunization/covid-19-vaccination . Accessed: 23.03.2022.
  • 12. Africa CDC. Avaible from: https://africacdc.org/covid-19-vaccination/ . Accessed: 23.03.2022.
  • 13. Ariën, K. K., Heyndrickx, L., Michiels, J., Vereecken, K., Van Lent, K., Coppens, S. et al. Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. NPJ Vaccines. 2022;7(1):35.
  • 14. Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med, 2022;386(5):492-494.
  • 15. McLaughlin, J., & Castrodale, L. Effectiveness of COVID-19 Vaccine Booster Dose Against COVID-19 During the SARS-CoV-2 B. 1.1. 529 (Omicron) Wave - Alaska, December 2021–January 2022. State of Alaska Epidemiology Bulletin 2022;02.
  • 16. Zhang, W., Huang, L., Ye, G., Geng, Q., Ikeogu, N., Harris, M. et al. Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant. Cell Mol Immunol. 2022;19(3):445-446.
  • 17. Thompson, M. G., Natarajan K., Irving S. A., Rowley E. A., Griggs E. P., Gaglani M., et al., Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-145.
  • 18. Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., et al. Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC. medRxiv. 2022.
  • 19. Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Amir, O., Freedman, L., ... & Milo, R. (2022). Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. New England Journal of Medicine, 386(18), 1712-1720. 20. Hause, A. M. (2022). Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged≥ 50 Years—United States, March 29, 2022–July 10, 2022. MMWR. Morbidity and Mortality Weekly Report, 71.
Year 2022, Volume: 31 Issue: 4, 249 - 253, 30.12.2022
https://doi.org/10.17827/aktd.1097876

Abstract

References

  • 1. Vitiello, A., Ferrara, F., Auti, A. M., Di Domenico, M., & Boccellino, M. Advances in the Omicron variant development. J Intern Med. 2022.
  • 2. Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G. et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327(7):639-651.
  • 3. Chenchula, S., & Karunakaran, P. Current Evidence on Efficacy of COVID‐19 Booster Dose Vaccination Against the Omicron Variant. A Systematic Review. J Med Virol. 2022.
  • 4. Shen, X. Boosting immunity to Omicron. Nat Med. 2022;1-2.
  • 5. Hart, J. D., Chokephaibulkit, K., Mayxay, M., Ong-Lim, A. L. T., Saketa, S. T., Russell F. M. COVID-19 vaccine boosters in the Asia-Pacific region in the context of Omicron. Lancet Reg Health West Pac. 2022;100404.
  • 6. Mehta, S., Gambhir, R. S., Singh, B., Goel, R., Ghuman, K. S., Aggarwal, A. COVID-19 Update: Omicron Variant–A New Emerging Threat. Rocz Panstw Zakl Hig. 2022;73(1):13-16.
  • 7. Chavda, V. P., & Apostolopoulos, V. Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?. Vaccines. 2022;10(3):367.
  • 8. Our World In Data. Avaible from: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL . Accessed: 23.03.2022.
  • 9. Vaccine Tracker ECDC. Avaible from: https://vaccinetracker.ecdc.europa.eu/public/extensions/covid-19/vaccine-tracker.html#uptake-tab . Accessed: 23.03.2022.
  • 10. COVID CDC. Avaible from: https://covid.cdc.gov/covid-data-tracker/ . Accessed: 23.03.2022.
  • 11. WHO South East Asia. Avaible from: https://www.who.int/southeastasia/health-topics/immunization/covid-19-vaccination . Accessed: 23.03.2022.
  • 12. Africa CDC. Avaible from: https://africacdc.org/covid-19-vaccination/ . Accessed: 23.03.2022.
  • 13. Ariën, K. K., Heyndrickx, L., Michiels, J., Vereecken, K., Van Lent, K., Coppens, S. et al. Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. NPJ Vaccines. 2022;7(1):35.
  • 14. Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med, 2022;386(5):492-494.
  • 15. McLaughlin, J., & Castrodale, L. Effectiveness of COVID-19 Vaccine Booster Dose Against COVID-19 During the SARS-CoV-2 B. 1.1. 529 (Omicron) Wave - Alaska, December 2021–January 2022. State of Alaska Epidemiology Bulletin 2022;02.
  • 16. Zhang, W., Huang, L., Ye, G., Geng, Q., Ikeogu, N., Harris, M. et al. Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant. Cell Mol Immunol. 2022;19(3):445-446.
  • 17. Thompson, M. G., Natarajan K., Irving S. A., Rowley E. A., Griggs E. P., Gaglani M., et al., Effectiveness of a third dose of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-145.
  • 18. Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., et al. Fourth Dose COVID mRNA Vaccines' Immunogenicity & Efficacy Against Omicron VOC. medRxiv. 2022.
  • 19. Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Amir, O., Freedman, L., ... & Milo, R. (2022). Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. New England Journal of Medicine, 386(18), 1712-1720. 20. Hause, A. M. (2022). Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged≥ 50 Years—United States, March 29, 2022–July 10, 2022. MMWR. Morbidity and Mortality Weekly Report, 71.
There are 19 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Review
Authors

Ezgi Çebi 0000-0001-7629-4170

Meltem Çöl 0000-0001-7089-1644

Publication Date December 30, 2022
Acceptance Date October 27, 2022
Published in Issue Year 2022 Volume: 31 Issue: 4

Cite

AMA Çebi E, Çöl M. 3 Doz mRNA COVID-19 Aşısı ve SARS-CoV-2 Omicron Varyantı Enfeksiyonu Arasındaki İlişki. aktd. December 2022;31(4):249-253. doi:10.17827/aktd.1097876